Hollis-Eden Pharmaceuticals, Inc.

Phase I clinical study on NEUMUNE begins

Published in Drug Law Weekly, May 3rd, 2005

Hollis-Eden Pharmaceuticals, Inc., has initiated the first in a series of Phase I safety and pharmacokinetic (PK) clinical trials with NEUMUNE (HE2100), its investigational immune regulating hormone (IRH) for the treatment of Acute Radiation Syndrome (ARS).

The company also stated that it continues to expect to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the first half of 2005 to initiate clinical studies in the U.S. Safety and PK study results are expected to be available in a timeframe that enables Hollis-Eden to initiate a pivotal efficacy study in non-human primates in the second half of 2005.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry